365 related articles for article (PubMed ID: 18498916)
21. Mycophenolic acid concentrations are associated with cardiac allograft rejection.
DeNofrio D; Loh E; Kao A; Korecka M; Pickering FW; Craig KA; Shaw LM
J Heart Lung Transplant; 2000 Nov; 19(11):1071-6. PubMed ID: 11077224
[TBL] [Abstract][Full Text] [Related]
22. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
23. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
24. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Cox S; Maseck D; Zhang K; Sherbotie JR; Ellis EN; James LP; Ward RM; Vinks AA
Ther Drug Monit; 2012 Dec; 34(6):671-9. PubMed ID: 23131697
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
[TBL] [Abstract][Full Text] [Related]
26. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
[TBL] [Abstract][Full Text] [Related]
28. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
[TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.
Naesens M; Kuypers DR; Verbeke K; Vanrenterghem Y
Transplantation; 2006 Oct; 82(8):1074-84. PubMed ID: 17060857
[TBL] [Abstract][Full Text] [Related]
30. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
van Gelder T; Silva HT; de Fijter JW; Budde K; Kuypers D; Tyden G; Lohmus A; Sommerer C; Hartmann A; Le Meur Y; Oellerich M; Holt DW; Tönshoff B; Keown P; Campbell S; Mamelok RD
Transplantation; 2008 Oct; 86(8):1043-51. PubMed ID: 18946341
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
Pape L; Ehrich JH; Offner G
Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
33. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients.
Gelone DK; Park JM; Lake KD
Pharmacotherapy; 2007 Sep; 27(9):1272-8. PubMed ID: 17723081
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.
Pescovitz MD; Vincenti F; Hart M; Melton L; Whelchel J; Mulgaonkar S; McKay D; Leung M; Calleja E; Bouw MR
Br J Clin Pharmacol; 2007 Dec; 64(6):758-71. PubMed ID: 17555465
[TBL] [Abstract][Full Text] [Related]
35. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.
Bunchman T; Navarro M; Broyer M; Sherbotie J; Chavers B; Tönshoff B; Birk P; Lerner G; Lirenman D; Greenbaum L; Walker R; Zimmerhackl LB; Blowey D; Clark G; Ettenger R; Arterburn S; Klamerus K; Fong A; Tang H; Thomas S; Ramos E
Pediatr Nephrol; 2001 Dec; 16(12):978-84. PubMed ID: 11793083
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil in liver transplantation.
McDiarmid SV
Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
[TBL] [Abstract][Full Text] [Related]
37. Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation.
Roan JN; Chou CH; Hsu CH; Wu SY; Huang YC; Yang YJ; Luo CY
Ann Transplant; 2013 Feb; 18():43-52. PubMed ID: 23792500
[TBL] [Abstract][Full Text] [Related]
38. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
[TBL] [Abstract][Full Text] [Related]
40. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
